01—Abstract
Summary
Summary of the 8-K filed May 12, 2025. Cited figures are marked; the original filing is the authoritative source.
On May 12, 2025, Royalty Pharma plc held its 2025 Annual General Meeting and Special Meeting of Shareholders, with 493,716,628 Class A and Class B ordinary shares present or represented by proxy, representing 85.96%a of the combined voting power entitled to vote and constituting a quorum.
Shareholders voted on 15 proposals described in the definitive proxy statement filed April 11, 2025. The most consequential items relate to the "Internalization Proposal" and the related Membership Interest Purchase Agreement, which the filing references in Proposals 1 and 2, along with the non-binding advisory vote on compensation payable to named executive officers in connection with the Transaction (Proposal 3). Several proposals passed with strong support, including the ratification of Ernst & Young LLP as independent registered public accounting firm (493,521,988 for, 116,396 against), the approval of the U.K. statutory accounts for the fiscal year ended December 31, 2023 (493,059,166 for, 98,388 against), and the re-appointment of Ernst & Young Chartered Accountants as U.K. statutory auditor.
Nine directors were nominated for election to serve until the 2026 Annual General Meeting. Ted Love, M.D. received the most opposition among nominees, with 31,393,111 votes against, while the other eight nominees each received between 2,473,998 and 22,097,928 votes against. Shareholder support was more mixed on executive pay matters.
The advisory vote on named executive officer compensation (Proposal 7) received 403,157,465 votes for and 36,842,162 against, and the U.K. directors' remuneration policy (Proposal 10) received 398,711,622 for and 41,343,662 against. The filing does not state the outcome of each proposal beyond the vote tallies themselves, so investors should review the proxy statement for the proposals' full terms.
02—Key points
Key Highlights
- Annual General Meeting and Special Meeting held May 12, 2025, with a quorum of 493,716,628 shares representing 85.96% of combined voting power.
- Proposal 2 sought approval of the Membership Interest Purchase Agreement and related transaction documents, share issuance authority, and amended articles of association; it received 440,522,948 votes for and 74,301 against.
- Proposal 1 authorized the chairman to adjourn the meeting to solicit additional votes if insufficient votes were cast for the Internalization Proposal; it received 429,870,979 votes for and 10,759,799 against.
- Proposal 3, a non-binding advisory vote on compensation payable to named executive officers in connection with the Transaction, received 420,544,944 votes for and 20,056,306 against.
- Nine directors were nominated, with Ted Love, M.D. receiving the highest opposition at 31,393,111 votes against.
- Ernst & Young LLP ratification as independent registered public accounting firm received 493,521,988 votes for and 116,396 against.
- Advisory vote on named executive officer compensation (Proposal 7) received 403,157,465 votes for and 36,842,162 against.
03—Questions
Frequently Asked Questions
What were the main proposals shareholders voted on at the May 12, 2025 meeting?
Shareholders voted on 15 proposals, the most significant of which concerned the Internalization Proposal and the Membership Interest Purchase Agreement with related transaction documents, share issuance authority, and amended articles of association. Other items included executive compensation votes, adoption of the 2025 Equity Incentive Plan, share purchase arrangements, director elections, auditor matters, and share allotment authorities.
Did shareholders approve the Membership Interest Purchase Agreement and related transaction?
Proposal 2 received 440,522,948 votes for, 74,301 against, and 152,935 abstentions, with 52,966,444 broker non-votes. The filing reports vote tallies but does not itself state the resulting determination; the proxy statement describes the transaction in more detail.
How did shareholders vote on executive compensation?
The non-binding advisory vote on named executive officer compensation (Proposal 7) received 403,157,465 votes for and 36,842,162 against. A separate advisory vote on compensation tied to the Transaction (Proposal 3) received 420,544,944 votes for and 20,056,306 against.
Which director nominee faced the most shareholder opposition?
Ted Love, M.D. received 408,610,518 votes for, 31,393,111 against, and 746,555 abstentions. Pablo Legorreta received the next highest opposition with 22,097,928 votes against.
04—Continue